pT3-EF1aH N90-beta-catenin Citations (4)

Originally described in: Distinct pathways of genomic progression to benign and malignant tumors of the liver.
Tward AD, Jones KD, Yant S, Cheung ST, Fan ST, Chen X, Kay MA, Wang R, Bishop JM Proc Natl Acad Sci U S A. 2007 Sep 11;104(37):14771-6. Epub 2007 Sep 4. PubMed Journal

---

Articles Citing pT3-EF1aH N90-beta-catenin

Articles
Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by beta-Catenin Mutations. Adebayo Michael AO, Ko S, Tao J, Moghe A, Yang H, Xu M, Russell JO, Pradhan-Sundd T, Liu S, Singh S, Poddar M, Monga JS, Liu P, Oertel M, Ranganathan S, Singhi A, Rebouissou S, Zucman-Rossi J, Ribback S, Calvisi D, Qvartskhava N, Gorg B, Haussinger D, Chen X, Monga SP. Cell Metab. 2019 May 7;29(5):1135-1150.e6. doi: 10.1016/j.cmet.2019.01.002. Epub 2019 Jan 31. PubMed
De novo and salvage purine synthesis pathways across tissues and tumors. Tran DH, Kim D, Kesavan R, Brown H, Dey T, Soflaee MH, Vu HS, Tasdogan A, Guo J, Bezwada D, Al Saad H, Cai F, Solmonson A, Rion H, Chabatya R, Merchant S, Manales NJ, Tcheuyap VT, Mulkey M, Mathews TP, Brugarolas J, Morrison SJ, Zhu H, DeBerardinis RJ, Hoxhaj G. Cell. 2024 Jul 11;187(14):3602-3618.e20. doi: 10.1016/j.cell.2024.05.011. Epub 2024 May 31. PubMed
FDX1 downregulation activates mitophagy and the PI3K/AKT signaling pathway to promote hepatocellular carcinoma progression by inducing ROS production. Sun B, Ding P, Song Y, Zhou J, Chen X, Peng C, Liu S. Redox Biol. 2024 Sep;75:103302. doi: 10.1016/j.redox.2024.103302. Epub 2024 Aug 5. PubMed
SLC13A3 is a major effector downstream of activated beta-catenin in liver cancer pathogenesis. Zhao W, Wang X, Han L, Zhang C, Wang C, Kong D, Zhang M, Xu T, Li G, Hu G, Luo J, Yee SW, Yang J, Stahl A, Chen X, Zhang Y. Nat Commun. 2024 Aug 30;15(1):7522. doi: 10.1038/s41467-024-51860-2. PubMed

If you have published an article using this material, please email us at to have your article added to this page.